Sanofi, GSK Delay COVID Vaccine On Low Response In Older Adults

Sanofi and GlaxoSmithKline announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.